Last mentioned: Mar 12, 2026
US healthcare payers and providers are deploying sophisticated AI tools to automate claims and denials, escalating a long-standing financial conflict. This technological shift promises efficiency but risks creating an 'AI vs. AI' stalemate that could impact patient care access.
Waystar (NASDAQ: WAY) is navigating a divided Wall Street as Needham & Company lowered its price target to $33.00, citing potential growth headwinds. This move contrasts with Truist Financial's $38.00 valuation, highlighting a widening gap in expectations for the healthcare payment platform's market penetration.
Waystar (NASDAQ: WAY) is facing a divergent outlook from major analysts as Needham & Company LLC lowered its price target to $33.00, while Truist Financial established a more optimistic $38.00 target. These updates come as the healthcare payments SaaS provider navigates a complex post-IPO landscape characterized by shifting provider spending patterns.